keyword
MENU ▼
Read by QxMD icon Read
search

muscle invasive urothelial bladder cancer

keyword
https://www.readbyqxmd.com/read/28064545/androgen-receptor-activation-a-prospective-therapeutic-target-for-bladder-cancer
#1
Taichi Mizushima, Kathleen A Tirador, Hiroshi Miyamoto
Patients with non-muscle-invasive or muscle-invasive bladder cancer undergoing surgery and currently available conventional therapy remain having a high risk of tumor recurrence or progression, respectively. Novel targeted molecular therapy is therefore expected to improve patient outcomes. Meanwhile, substantially higher incidence of bladder cancer in men has prompted research on androgen-mediated androgen receptor (AR) signaling in this malignancy. Indeed, preclinical evidence has suggested that AR signaling plays an important role in urothelial carcinogenesis and tumor outgrowth as well as resistance to some of the currently available conventional non-surgical therapies...
January 9, 2017: Expert Opinion on Therapeutic Targets
https://www.readbyqxmd.com/read/28043166/pharmacokinetic-drug-evaluation-of-atezolizumab-for-the-treatment-of-locally-advanced-or-metastatic-urothelial-carcinoma
#2
Rutveej Patel, Megan Bock, Charles F Polotti, Sammy Elsamra
Muscle invasive bladder cancer (MIBC) is difficult to manage for patients who progress during or after initial chemotherapy regimens. Current regimens offer low response rates with high toxicities. The advent of immune checkpoint inhibitors may represent a new opportunity for effective management of these patients. Areas covered: Atezolizumab is an engineered humanized monoclonal immunoglobulin G1 antibody that binds selectively to PD-L1 and prevents its interaction with PD-1 and B7-1. It is administered intravenously and is given every 3 weeks as long as there is no evidence of tumor progression...
February 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/28040351/clinical-outcomes-of-patients-with-histologic-variants-of-urothelial-cancer-treated-with-trimodality-bladder-sparing-therapy
#3
Ross E Krasnow, Michael Drumm, Hannah J Roberts, Andrzej Niemierko, Chin-Lee Wu, Shulin Wu, Jing Zhang, Niall M Heney, Matthew F Wszolek, Michael L Blute, Adam S Feldman, Richard J Lee, Anthony L Zietman, William U Shipley, Jason A Efstathiou
BACKGROUND: Trimodality bladder-sparing therapy (TMT) is an acceptable treatment for selected patients with muscle-invasive urothelial cancer. Outcomes of TMT in histologic variants remains largely unknown. OBJECTIVE: To compare outcomes of pure urothelial carcinoma (PUC) to variant urothelial carcinoma (VUC) after TMT. DESIGN, SETTING, AND PARTICIPANTS: Retrospective study of patients treated with TMT at a single cancer center from 1993 until 2013...
December 28, 2016: European Urology
https://www.readbyqxmd.com/read/28035618/who-1973-grade-3-and-infiltrative-growth-pattern-proved-aberrant-e-cadherin-expression-tends-to-be-of-predictive-value-for-progression-in-a-series-of-stage-t1-high-grade-bladder-cancer-after-organ-sparing-approach
#4
Wolfgang Otto, Johannes Breyer, Sonja Herdegen, Fabian Eder, Simone Bertz, Matthias May, Roman Mayr, Eva M Lausenmeyer, Stefan Denzinger, Bas W G van Rhijn, Maximilian Burger, Arndt Hartmann
PURPOSE: Stage pT1 urothelial bladder cancer (UBC) is characterized as a challenging subentity of urothelial carcinoma with an unforeseeable clinical course. In addition to more or less established clinical and histopathological features, we evaluated the role of epithelial-mesenchymal transition (EMT) marker E-cadherin, shown to be of prognostic value in muscle-invasive disease, regarding the prognosis of stage pT1 high-grade (hg) UBC. METHODS: Tissue of 226 stage pT1 hg UBC patients from transurethral resection could be immunostained for E-cadherin...
December 29, 2016: International Urology and Nephrology
https://www.readbyqxmd.com/read/28035325/effect-of-neoadjuvant-chemotherapy-on-renal-function-following-radical-cystectomy-is-there-a%C3%A2-meaningful-impact
#5
Thenappan Chandrasekar, Neil Pugashetti, Blythe Durbin-Johnson, Marc A Dall'Era, Christopher P Evans, Ralph W deVere White, Stanley A Yap
Objective: To evaluate the patterns of impact of neoadjuvant chemotherapy (NAC) on renal function across the initial year following treatment for muscle-invasive bladder cancer (MIBC) with radical cystectomy (RC). Methods: We reviewed the charts of 241 patients who underwent RC for urothelial carcinoma of the bladder between 2003-14 at our institution. Renal function was evaluated at multiple time points (pre-chemotherapy, pre-operatively, post-operatively, 6-12 months follow-up), and then classified by CKD staging...
October 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/28035322/micropapillary-bladder-cancer-insights-from-the-national-cancer-database
#6
Wilson Sui, Justin T Matulay, Maxwell B James, Ifeanyi C Onyeji, Marissa C Theofanides, Arindam RoyChoudhury, G Joel DeCastro, Sven Wenske
Introduction: Micropapillary bladder cancer (MPBC) is a variant histology of urothelial carcinoma (UC) that is associated with poor outcomes however given its rarity, little is known outside of institutional reports. We sought to use a population-level cancer database to assess survival outcomes in patients treated with surgery, radiation therapy and/or chemotherapy. Materials and Methods: The National Cancer Database (NCDB) was queried for all cases of MPBC and UC using International Classification of Disease-O-3 morphologic codes between 2004-2014...
October 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/28035321/patterns-of-bladder-preservation-therapy%C3%A2-utilization-for-muscle-invasive-bladder-cancer
#7
Tracy L Rose, Allison M Deal, Sylvain Ladoire, Gilles Créhange, Matthew D Galsky, Jonathan E Rosenberg, Joaquim Bellmunt, Akhila Wimalasingham, Yu-Ning Wong, Lauren C Harshman, Simon Chowdhury, Guenter Niegisch, Michalis Liontos, Evan Y Yu, Sumanta K Pal, Ronald C Chen, Andrew Z Wang, Matthew E Nielsen, Angela B Smith, Matthew I Milowsky
Background: Trimodality bladder preservation therapy (BPT) in muscle invasive bladder cancer (MIBC) includes a maximal transurethral resection followed by concurrent chemoradiotherapy as an alternative to radical cystectomy (RC) in appropriately selected patients, or as a treatment option in non-cystectomy candidates. Several chemotherapy regimens can be used in BPT, but little is known about current practice patterns. Objective: To describe utilization patterns of BPT and associated survival outcomes in MIBC...
October 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/28013415/prognostic-impact-of-preoperative-anemia-on-non-muscle-invasive-bladder-carcinoma-treated-with-greenlight-laser-vaporization
#8
Fei Luo, Ya-Shen Wang, Yan-Hui Su, Zhi-Hua Zhang, Hong-Hong Sun, Jian Li
In this study, we aimed to evaluate the impact of preoperative anemia (PA) on oncological outcomes among patients with non-muscle-invasive bladder cancer (NMIBC) treated with GreenLight laser vaporization of bladder tumor (PV-BT). Between January 2010 and December 2015, 407 patients with NMIBC who underwent PV-BT surgery were stratified into normal and anemia groups based on the World Health Organization classification (anemia cutoff value: hemoglobin level, <13.0 m g/dL in men and <12.0 mg/dL in women)...
December 24, 2016: Lasers in Medical Science
https://www.readbyqxmd.com/read/28004470/carbonic-anhydrase-2-is-a-novel-invasion-associated-factor-in-urinary-bladder-cancers
#9
Hirokazu Tachibana, Min Gi, Minoru Kato, Shotaro Yamano, Masaki Fujioka, Anna Kakehashi, Yukiyoshi Hirayama, Yuki Koyama, Satoshi Tamada, Tatsuya Nakatani, Hideki Wanibuchi
Rat bladder cancer is nearly always papillary non-invasive urothelial carcinoma (UC). To establish an animal model mimicking invasive UC that arises from papillary non-invasive UC in the bladder, male human c-Ha-ras proto-oncogene transgenic rats (Hras128) were treated with 0.05% N-butyl-N-(hydroxybutyl)nitrosameine (BBN) in their drinking water and/or 0.1% phenylethyl isothiocyanate (PEITC) in their diet as follows: BBN (8 weeks)→PEITC (8 weeks); PEITC (8 weeks)→BBN (8 weeks); BBN alone (16 weeks); PEITC alone (16 weeks); no-treatment...
December 22, 2016: Cancer Science
https://www.readbyqxmd.com/read/27980085/the-feasibility-and-effectiveness-of-robot-assisted-radical-cystectomy-after-neoadjuvant-chemotherapy-in-patients-with-muscle-invasive-bladder-cancer
#10
Takuya Koie, Chikara Ohyama, Hayato Yamamoto, Atsushi Imai, Shingo Hatakeyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Tohru Yoneyama, Yuki Tobisawa, Atsushi Yamauchi, Toru Shimazui, Mikinobu Ohtani
OBJECTIVES: The aim of this study was to compare 29 muscle-invasive bladder cancer patients who received neoadjuvant chemotherapy (NAC) followed by immediate robot-assisted radical cystectomy (RARC) with those who underwent minimum-incision endoscopic RC (MIE-RC). METHODS: We retrospectively reviewed the charts of 430 consecutive patients who underwent RC and bilateral pelvic node dissection (PLND) between May 1994 and July 2016. Our study focused on patients with MIBC who had histologically confirmed stage T2-T4aN0M0 urothelial carcinoma of the bladder and received NAC prior to surgery...
December 15, 2016: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27960233/iatrogenic-changes-in-the-urinary-tract
#11
REVIEW
Antonio Lopez-Beltran, Gladell P Paner, Rodolfo Montironi, Maria R Raspollini, Liang Cheng
A handful of therapeutic procedures are used to treat malignancies of the urinary tract, most frequently intravesical immunotherapy or chemotherapy, but also neoadjuvant systemic chemotherapy. These treatment modalities produce morphological changes in the urothelium that can be mistaken for carcinoma; in particular, these therapies frequently mimic urothelial carcinoma in situ (CIS) urothelial dysplasia or true invasive neoplasia. Drugs such as mitomycin C used after transurethral resection of bladder tumour to reduce recurrences, bacillus Calmette-Guérin (BCG) intravesical immunotherapy to treat high-risk non-muscle-invasive bladder cancer and urothelial CIS and platin-based systemic chemotherapy to improve postcystectomy disease-specific survival are examples of therapy-related atypia seen in the urinary tract...
January 2017: Histopathology
https://www.readbyqxmd.com/read/27920099/systematic-regional-lymph-node-dissection-for-upper-tract-urothelial-carcinoma-improves-patient-survival
#12
Hiroshi Furuse, Yuto Matsushita, Takashi Yajima, Taiki Kato, Takahisa Suzuki, Rikiya Matsumoto, Daisuke Motoyama, Takayuki Sugiyama, Atsushi Otsuka, Seiichiro Ozono
OBJECTIVE: Unlike for bladder cancer, the impact of regional lymph node dissection for upper tract urothelial carcinoma is unclear. We explored whether patient survival was influenced by systematic regional lymph node dissection, using resection templates according to the main tumor location, during radical nephroureterectomy for upper tract urothelial carcinoma. METHODS: The systematic regional lymph node dissection group was defined as cases in which the dissection of nodes and surrounding tissues followed the established template, and the non-systematic regional lymph node dissection group as cases undergoing limited or no lymph node dissection...
December 4, 2016: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27919942/a-single-intravesical-instillation-of-vax014-inhibits-orthotopic-superficial-bladder-tumor-implantation-to-increase-survival
#13
Bryan M Hancock, Kathleen L McGuire, Shingo Tsuji, Katherine Reil, Veronica Hernandez, Matthew J Giacalone, W T Godbey
BACKGROUND/AIM: VAX014 minicells (VAX014) have been previously characterized as an integrin-specific oncolytic biotherapeutic agent. The present study was designed to evaluate the potential of VAX014 as an immediate post-operative intravesical adjuvant therapy in the treatment of non-muscle invasive bladder cancer (NMIBC). MATERIALS AND METHODS: The ability of VAX014 to kill a panel of dissociated urothelial carcinoma cell lines was tested in vitro. In vivo experiments were conducted using a single intravesical dose of VAX014 in the anti-implantation variation of the MB49 syngeneic orthotopic bladder cancer model with tumor implantation and overall survival rates serving as study endpoints...
2016: Anticancer Research
https://www.readbyqxmd.com/read/27913867/comparison-of-different-concepts-for-interpretation-of-chromosomal-aberrations-in-urothelial-cells-detected-by-fluorescence-in-situ-hybridization
#14
Johannes Mischinger, Lutz Philipp Guttenberg, Jörg Hennenlotter, Georgios Gakis, Stefan Aufderklamm, Steffen Rausch, Eva Neumann, Jens Bedke, Stefan Kruck, Christian Schwentner, Arnulf Stenzl, Tilman Todenhöfer
PURPOSE: Urine fluorescence in situ hybridization (FISH) has become a broadly used marker for noninvasive detection of bladder cancer (BC). However, it has been discussed whether the interpretation algorithm proposed by the manufacturer could be improved. Aim of the present study was to compare alternative evaluation strategies of FISH for detection of BC. METHODS: We included 1048 patients suspicious for BC, who underwent urine FISH examination before cystoscopy (diagnostic cohort)...
December 2, 2016: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/27900539/seom-clinical-guideline-for-treatment-of-muscle-invasive-and-metastatic-urothelial-bladder-cancer-2016
#15
M Lázaro, E Gallardo, M Doménech, Á Pinto, A González Del Alba, J Puente, O Fernández, A Font, N Lainez, S Vázquez
The goal of this article is to provide recommendations for the diagnosis and treatment of muscle-invasive and metastatic bladder cancer. The diagnosis of muscle-invasive bladder cancer is made by pathologic evaluation after transurethral resection. Recently, a molecular classification has been proposed. Staging of muscle-invasive bladder cancer must be done by computed tomography scans of the chest, abdomen and pelvis and classified on the basis of UICC system. Radical cystectomy and lymph node dissection are the treatment of choice...
December 2016: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/27895377/frequency-and-predictors-of-recurrence-of-bladder-tumour-on-first-check-cystoscopy-a-tertiary-care-hospital-experience
#16
Muhammad Farhan, Syed Muhammad Nazim, Jibran Ahmed, Muhammad Hammad Ather
OBJECTIVE: To determine the frequency and predictors of non-muscle invasive bladder tumour recurrence on first-check cystoscopy after transurethral resection of bladder tumour. METHODS: This cross-sectional study was conducted at the Aga Khan University Hospital, Karachi, from April to November 2014, and comprised patients with a suspected newly-diagnosed urothelial cancer. Patients with non-muscle invasive disease with complete resection of all visible lesions along with deep biopsy from the tumour base were included...
October 2016: JPMA. the Journal of the Pakistan Medical Association
https://www.readbyqxmd.com/read/27887951/a-multi-institutional-comparison-of-clinicopathologic-characteristics-and-oncologic-outcomes-of-upper-tract-urothelial-carcinoma-in-china-and-the-united-states
#17
Nirmish Singla, Dong Fang, Xiaohong Su, Zhengqing Bao, Zhenpeng Cao, Syed M Jafri, Gengyan Xiong, Lei Zhang, Ryan Hutchinson, Arthur Sagalowsky, Yair Lotan, Xuesong Li, Liqun Zhou, Jay D Raman, Vitaly Margulis
PURPOSE: To evaluate differences in clinicopathologic characteristics and oncologic outcomes between upper-tract urothelial carcinoma (UTUC) patients in China and the United States (U.S.). METHODS: Clinicopathologic and oncologic outcomes data of UTUC patients treated surgically at tertiary care medical facilities in the U.S. or China from 1998-2015 were retrospectively compiled. Baseline demographics, comorbidities, and pathologic features were evaluated. Oncologic endpoints including intravesical recurrence and cancer-specific survival (CSS) were obtained following exclusion of patients who received systemic chemotherapy...
November 22, 2016: Journal of Urology
https://www.readbyqxmd.com/read/27843210/an-audit-of-early-complications-of-radical-cystectomy-using-clavien-dindo-classification
#18
Nitesh Patidar, Priyank Yadav, Sanjoy Kumar Sureka, Varun Mittal, Rakesh Kapoor, Anil Mandhani
INTRODUCTION: Despite the major improvements in surgical technique and perioperative care, radical cystectomy (RC) remains a major operative procedure with a significant morbidity and mortality. The present study analyzes the early complications of RC and urinary diversion using a standardized reporting system. MATERIALS AND METHODS: Modified Clavien-Dindo classification was used to retrospectively assess the peri-operative course of 212 patients who had RC with urinary diversion between October 2003 and October 2014 at a single institution...
October 2016: Indian Journal of Urology: IJU: Journal of the Urological Society of India
https://www.readbyqxmd.com/read/27804056/smoking-status-usual-adult-occupation-and-risk-of-recurrent-urothelial-bladder-carcinoma-data-from-the-cancer-genome-atlas-tcga-project
#19
Amber N Wilcox, Debra T Silverman, Melissa C Friesen, Sarah J Locke, Daniel E Russ, Noorie Hyun, Joanne S Colt, Jonine D Figueroa, Nathaniel Rothman, Lee E Moore, Stella Koutros
PURPOSE: Tobacco smoking and occupational exposures are the leading risk factors for developing urothelial bladder carcinoma (UBC), yet little is known about the contribution of these two factors to risk of UBC recurrence. We evaluated whether smoking status and usual adult occupation are associated with time to UBC recurrence for 406 patients with muscle-invasive bladder cancer submitted to The Cancer Genome Atlas (TCGA) project. METHODS: Kaplan-Meier and Cox proportional hazard methods were used to assess the association between smoking status, employment in a high-risk occupation for bladder cancer, occupational diesel exhaust exposure, and 2010 Standard Occupational Classification group and time to UBC recurrence...
December 2016: Cancer Causes & Control: CCC
https://www.readbyqxmd.com/read/27785430/management-of-muscle-invasive-locally-advanced-and-metastatic-urothelial-carcinoma-of-the-bladder-a-literature-review-with-emphasis-on-the-role-of-surgery
#20
REVIEW
Mohammad Abufaraj, Kilian Gust, Marco Moschini, Beat Foerster, Francesco Soria, Romain Mathieu, Shahrokh F Shariat
Locally advanced (T3b, T4 and N1-N3) and metastatic urothelial bladder cancer (BCa) is a lethal disease with poor survival outcomes. Combination chemotherapy remains the treatment of choice in patients with metastatic disease and an important part of treatment in addition to radical cystectomy (RC) in patients with locally advanced tumour. Approximately half of patients who underwent RC for muscle invasive BCa relapse after surgery with either local recurrence or distant metastasis. This review focuses on the management of muscle invasive, locally advanced and metastatic BCa with emphasis on the role of surgery; to summarize the current knowledge in order to enhance clinical decision-making and counselling process...
October 2016: Translational Andrology and Urology
keyword
keyword
105932
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"